TN TNDM Tandem Diabetes Care, Inc. Загрузка... : Бычьи и медвежьи мнения аналитиков

DexCom's G7 15-day integration with Tandem's pumps is a key milestone; Tandem's installed base now has access to the new 15-day sensor which is likely a tailwind for Tandem's pump sales in the near term.

Tandem is trading at ~1x projected 2026 revenue ($1.075B) with recurring revenue from PayGo, positive EBITDA trajectory, and a pipeline for a tubeless pump to compete with Omnipod. Wall Street is discounting temporary PayGo transition headwinds, but the shift multiplies lifetime patient value. As margins expand and revenue grows, the stock could re-rate violently higher or attract a buyout at 30-50% premium. A high-risk/high-reward long position betting on execution or acquisition in a sticky medical device market. FDA delays, GLP-1 fears (though irrelevant to T1D), Medicaid reimbursement issues, execution risk on PayGo transition, competition from Insulet's Omnipod, and community comments suggesting endocrinologists favor Omnipod.

Insulet is pivoting sales messaging to emphasize clinical performance (A1C reduction) as a counter to competitive claims, while maintaining its form-factor and user-experience edge. — Enhanced clinical pitch could protect market share against tube pump competitors and sustain growth from new MDI converts.